Streamlining Impurity Analysis in Atorvastatin with the ACQUITY™ QDa™ II Mass Detector for Enhanced Detection and Quantification

Significance of the Topic

Impurity profiling in pharmaceutical active ingredients is critical for ensuring patient safety and product efficacy. Atorvastatin, widely prescribed to lower LDL cholesterol, can develop trace impurities during synthesis or storage, which must be monitored according to ICH-Q3 guidelines at a qualification threshold of 0.15%. Combining traditional UV detection with mass detection enhances sensitivity, structural characterization, and reliable quantification of known and unknown impurities.

Objectives and Study Overview

This application note demonstrates a streamlined workflow integrating the ACQUITY QDa II Mass Detector with UV chromatography for routine atorvastatin impurity analysis. The goals were:

• To assess detection and quantification of related impurities A, C, and I at ≤0.15% relative to the API.
• To apply in-source fragmentation (pseudo-MS/MS) for structural insights into unknown impurities.
• To highlight the Empower CDS software for compliant data processing and reporting.

Used Instrumentation

• ACQUITY UPLC H-Class System with FTN-R Sample Manager
• ACQUITY QDa II Mass Detector (ESI+, positive mode)
• Photodiode Array Detector (PDA)
• ACQUITY UPLC CSH Phenyl-Hexyl column, 1.7 µm, 2.1×100 mm
• Empower Chromatography Data System v3.0

Methodology and Instrumentation

Atorvastatin calcium and impurities A, C, and I were dissolved in methanol and diluted in 40:60 H2O:ACN. Separation employed a 27.5-minute gradient at 0.4 mL/min, 30 °C column temperature, and 10 °C sample tray. Mobile phases comprised 10 mM ammonium acetate (A) and ACN with 0.1% formic acid (B). Injection volume was 2 µL. The QDa II parameters included 1.1 kV capillary voltage, 600 °C desolvation, and 120 °C source temperature. Divert valve use minimized API signal for low-level impurity quantification.

Main Results and Discussion

• Method Development: Replacing THF with ammonium acetate buffer and formic acid shortened run time by ~60 minutes and reduced solvent use by 90% versus the pharmacopeial method. A phenyl-hexyl column improved separation of impurity C from the API.
• Linearity and Sensitivity: API and impurities showed linearity (1/X weighting) over 0.01–5.0 µg/mL (API) and 0.01–1.0 µg/mL (impurities), with R2 > 0.998 and residuals < 16%. The 20 pg on-column limit delivered S/N > 136.
• Quantification at 0.15% Threshold: A 75 µg/mL API sample spiked at 0.12% impurity mix yielded repeatable results (RSD < 9% except 13% for impurity A). Mass detection revealed additional unknown impurities and prevented UV overestimation due to co-elution.
• In-Source Fragmentation: Increasing cone voltage (35–50 V) generated fragment ions distinguishing degradation products and structural isomers, aiding impurity identification.
• Co-Elution Detection: Mass monitoring uncovered a photolytic degradant co-eluting with impurity A after 15 days, leading to overestimation by UV alone.
• Data Reporting: Empower CDS automated reporting accelerated batch review and compliance.

Benefits and Practical Applications

• Mass annotation of peaks for rapid impurity confirmation
• Accurate quantification below regulatory thresholds
• Structural profiling of unknowns via in-source fragmentation
• Detection of co-eluting degradants to avoid false positives
• Streamlined reporting for regulated environments

Future Trends and Opportunities

• Integration of high-resolution MS for more detailed structural elucidation
• Automation of impurity identification using machine learning
• Adoption of multiplexed detectors for simultaneous multi-attribute analysis
• In-line stability monitoring in continuous manufacturing

Conclusion

The integration of the ACQUITY QDa II Mass Detector with UV chromatography and Empower CDS affords a robust, efficient, and compliant workflow for atorvastatin impurity analysis. It delivers sensitive quantification, structural insights, and safeguards against analytical biases, accelerating product release and ensuring quality.

References

1. Vukkum P et al. Stress Degradation Behavior of Atorvastatin Calcium and Development of a Stability-Indicating LC Method. Sci Pharm. 2013;81(1):93–114.
2. ICH Q3A(R2) Impurities in Drug Substances. ICH Consensus Guideline. 2006.
3. European Pharmacopoeia 11th Ed. Council of Europe. 2022.
4. Shulyak N et al. Fast HPLC Method for Atorvastatin and Impurities. Scientia Pharm. 2021;89(2):16.
5. Piponski M et al. Stability Indicating HPLC for Atorvastatin Compounds. J Anal Pharm Res. 2018;7(4):450–457.
6. Stach J et al. Synthesis of Impurities and Degradation Products of Atorvastatin. Collect Czech Chem Commun. 2008;73(2):229–246.
7. Mornar A et al. LC-ESI-MS of Atorvastatin and Related Impurities. Anal Lett. 2010;43(18):2859–2871.